Exagen Inc. - Common Stock (NQ:XGN)

2.710 -0.140 (-4.91%)

Streaming Delayed Price Updated: 3:08 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

Exagen: Q3 Earnings Insights ↗

November 10, 2021

Exagen (NASDAQ:XGN) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exagen...

Via Benzinga

Exagen: Q2 Earnings Insights ↗

August 09, 2021

Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results. Quarterly Results Earnings per share were down 40.74% over the past year to ($0.38), which beat the...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Exagen Inc. (XGN) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

XGN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Looking Into Exagen's Return On Capital Employed ↗

September 14, 2021

Exagen (NASDAQ:XGN) brought in sales totaling $12.77 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 3.14%, resulting in a loss of $5.74...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

Exagen: Q1 Earnings Insights ↗

May 11, 2021

Shares of Exagen (NASDAQ:XGN) were flat after the company reported Q1 results. Quarterly Results Earnings per share were down 9.09% year over year to ($0.48), which missed the...

Via Benzinga

Exagen Stock Gains As Q2 Financials Surpass Street Expectations ↗

August 10, 2021

Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the...

Via Benzinga

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

Exagen Inc. (XGN) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

XGN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For May 11, 2021 ↗

May 11, 2021

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

Return On Capital Employed Overview: Exagen ↗

June 18, 2021

In Q1, Exagen (NASDAQ:XGN) posted sales of $10.59 million. Earnings were up 101.63%, but Exagen still reported an overall loss of $5.57 million. In Q4, Exagen brought in $12.67...

Via Benzinga

Exagen: Return On Capital Employed Insights ↗

June 03, 2021

During Q1, Exagen's (NASDAQ:XGN) reported sales totaled $10.59 million. Despite a 101.63% in earnings, the company posted a loss of $5.57 million. Exagen collected $12.67 million...

Via Benzinga

62 Biggest Movers From Yesterday ↗

May 13, 2021

Gainers Curis, Inc. (NASDAQ: CRIS) shares surged 65.5% to settle at $16.27 on Wednesday in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA...

Via Benzinga

Exagen Inc. (XGN) Q1 2021 Earnings Call Transcript ↗

May 12, 2021

XGN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021 ↗

April 15, 2021

Upgrades According to JP Morgan, the prior rating for Vipshop Holdings Ltd (NYSE:VIPS) was changed from Neutral to Overweight. In the fourth quarter, Vipshop Holdings...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.